 [1m([0moverall-effect-mortality after myocardial infarction-beta blocker[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[34m                Passages:[0m
[34m                [0m[1;34m1[0m[34m. Drug METOPROLOL TARTRATE: METOPROLOL TARTRATE decreases the risk of mortality after myocardial infarction. This conclusion is based on a large clinical study cited by the FDA, which[0m
[34mshowed that metoprolol reduced [0m[1;34m3[0m[34m-month mortality by [0m[1;34m36[0m[34m% in patients with suspected or definite myocardial infarction. Patients in the study received metoprolol both very early [0m[1;34m([0m[34mintravenously[0m[1;34m)[0m[34m and [0m
[34mduring a subsequent [0m[1;34m3[0m[34m-month period, while the placebo group did not receive any beta-blocker treatment during this time.[0m
[1;34m2[0m[34m. Drug LABETALOL: DO-NOT-KNOW[0m

[34mThe FDA label for LABETALOL does not contain information regarding its effect on mortality risk after a myocardial infarction. Therefore, it is not possible to determine from this data whether [0m
[34mLABETALOL increases or decreases the risk of mortality after myocardial infarction.[0m
[1;34m3[0m[34m. Drug ATENOLOL: ATENOLOL decreases the risk of mortality after myocardial infarction. This is based on the information provided by FDAHandler, which states that Atenolol is indicated for the [0m
[34mmanagement of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. The International Study of Infarct Survival [0m[1;34m([0m[34mISIS-[0m[1;34m1[0m[1;34m)[0m[34m, which [0m
[34mincluded over [0m[1;34m16[0m[34m,[0m[1;34m000[0m[34m patients, used atenolol to treat patients with acute myocardial infarction, suggesting a benefit in reducing cardiovascular mortality.[0m
[34m                ---------[0m
[34m                Does the beta blocker category of drugs increase the risk of[0m
[34m                mortality after myocardial infarction, decrease it, or is there no clear effect?[0m
[34m            [0m
 [1m([0moverall-effect-mortality after myocardial infarction-beta blocker[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0moverall-effect-mortality after myocardial infarction-beta blocker[1m)[0m [31m Entity.AGENT [0m
*[1m([0moverall-effect-mortality after myocardial infarction-beta blocker[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does the beta blocker category of drugs increase the risk of mortality after myocardial infarction, decrease it, or is there no clear effect?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"Passage 1 indicates that METOPROLOL TARTRATE decreases the risk of mortality after myocardial infarction, based on a large clinical study showing a 36% reduction in 3-month mortality."[0m[32m,[0m
[32m      [0m[32m"Passage 2 does not provide information on LABETALOL's effect on mortality risk after myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"Passage 3 states that ATENOLOL decreases the risk of mortality after myocardial infarction, with evidence from the International Study of Infarct Survival [0m[32m([0m[32mISIS-1[0m[32m)[0m[32m suggesting a benefit in [0m
[32mreducing cardiovascular mortality."[0m[32m,[0m
[32m      [0m[32m"Given that two of the beta blockers [0m[32m([0m[32mMETOPROLOL TARTRATE and ATENOLOL[0m[32m)[0m[32m have strong evidence supporting a decrease in mortality risk after myocardial infarction, and one beta blocker [0m[32m([0m[32mLABETALOL[0m[32m)[0m
[32mhas no information available, the overall effect of the beta blocker category can be inferred to decrease the risk of mortality after myocardial infarction."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"The beta blocker category of drugs decreases the risk of mortality after myocardial infarction."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-mortality after myocardial infarction-beta blocker[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0moverall-effect-mortality after myocardial infarction-beta blocker[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0moverall-effect-mortality after myocardial infarction-beta blocker[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does the beta blocker category of drugs increase the risk of mortality after myocardial infarction, decrease it, or is there no clear effect?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"Passage 1 indicates that METOPROLOL TARTRATE decreases the risk of mortality after myocardial infarction, based on a large clinical study showing a 36% reduction in 3-month mortality."[0m[34m,[0m
[34m      [0m[34m"Passage 2 does not provide information on LABETALOL's effect on mortality risk after myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"Passage 3 states that ATENOLOL decreases the risk of mortality after myocardial infarction, with evidence from the International Study of Infarct Survival [0m[34m([0m[34mISIS-1[0m[34m)[0m[34m suggesting a benefit in [0m
[34mreducing cardiovascular mortality."[0m[34m,[0m
[34m      [0m[34m"Given that two of the beta blockers [0m[34m([0m[34mMETOPROLOL TARTRATE and ATENOLOL[0m[34m)[0m[34m have strong evidence supporting a decrease in mortality risk after myocardial infarction, and one beta blocker [0m[34m([0m[34mLABETALOL[0m[34m)[0m
[34mhas no information available, the overall effect of the beta blocker category can be inferred to decrease the risk of mortality after myocardial infarction."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"The beta blocker category of drugs decreases the risk of mortality after myocardial infarction."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does the beta blocker category of drugs increase the risk of mortality after myocardial infarction, decrease it, or is there no clear effect?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. Passage [0m[1;31m1[0m[31m indicates that METOPROLOL TARTRATE decreases the risk of mortality after myocardial infarction, based on a large clinical study showing a [0m[1;31m36[0m[31m% reduction in [0m[1;31m3[0m[31m-month mortality.[0m
[1;31m2[0m[31m. Passage [0m[1;31m2[0m[31m does not provide information on LABETALOL's effect on mortality risk after myocardial infarction.[0m
[1;31m3[0m[31m. Passage [0m[1;31m3[0m[31m states that ATENOLOL decreases the risk of mortality after myocardial infarction, with evidence from the International Study of Infarct Survival [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m suggesting a benefit in reducing [0m
[31mcardiovascular mortality.[0m
[1;31m4[0m[31m. Given that two of the beta blockers [0m[1;31m([0m[31mMETOPROLOL TARTRATE and ATENOLOL[0m[1;31m)[0m[31m have strong evidence supporting a decrease in mortality risk after myocardial infarction, and one beta blocker [0m[1;31m([0m[31mLABETALOL[0m[1;31m)[0m[31m has[0m
[31mno information available, the overall effect of the beta blocker category can be inferred to decrease the risk of mortality after myocardial infarction.[0m
[31m        -----[0m
[31m        Final answer: The beta blocker category of drugs decreases the risk of mortality after myocardial infarction.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning provided is generally sound, but it may be too strong to conclude that the entire beta blocker category decreases the risk of mortality after myocardial infarction based[0m
[32msolely on evidence from two specific drugs [0m[32m([0m[32mMETOPROLOL TARTRATE and ATENOLOL[0m[32m)[0m[32m. While these drugs do provide evidence of a decreased risk, the absence of information on LABETALOL and potentially other [0m
[32mbeta blockers means that we cannot generalize the effect to the entire category without more comprehensive data. Therefore, the conclusion should be more cautiously stated, indicating that there is [0m
[32mevidence that some beta blockers may decrease the risk, but the effect for the category as a whole is not definitively established."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0moverall-effect-mortality after myocardial infarction-beta blocker[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning provided is generally sound, but it may be too strong to conclude that the entire beta blocker category decreases the risk of mortality after myocardial infarction based[0m
[34msolely on evidence from two specific drugs [0m[34m([0m[34mMETOPROLOL TARTRATE and ATENOLOL[0m[34m)[0m[34m. While these drugs do provide evidence of a decreased risk, the absence of information on LABETALOL and potentially other [0m
[34mbeta blockers means that we cannot generalize the effect to the entire category without more comprehensive data. Therefore, the conclusion should be more cautiously stated, indicating that there is [0m
[34mevidence that some beta blockers may decrease the risk, but the effect for the category as a whole is not definitively established."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0moverall-effect-mortality after myocardial infarction-beta blocker[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning provided is generally sound, but it may be too strong to conclude that the entire beta blocker category decreases the risk of mortality after myocardial infarction [0m
[31mbased solely on evidence from two specific drugs [0m[1;31m([0m[31mMETOPROLOL TARTRATE and ATENOLOL[0m[1;31m)[0m[31m. While these drugs do provide evidence of a decreased risk, the absence of information on LABETALOL and potentially [0m
[31mother beta blockers means that we cannot generalize the effect to the entire category without more comprehensive data. Therefore, the conclusion should be more cautiously stated, indicating that there[0m
[31mis evidence that some beta blockers may decrease the risk, but the effect for the category as a whole is not definitively established.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0moverall-effect-mortality after myocardial infarction-beta blocker[1m)[0m [31m Entity.USER [0m
 [1m([0moverall-effect-mortality after myocardial infarction-beta blocker[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0moverall-effect-mortality after myocardial infarction-beta blocker[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does the beta blocker category of drugs increase the risk of mortality after myocardial infarction, decrease it, or is there no clear effect?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"Passage 1 indicates that METOPROLOL TARTRATE decreases the risk of mortality after myocardial infarction, based on a large clinical study showing a 36% reduction in 3-month mortality."[0m[32m,[0m
[32m      [0m[32m"Passage 2 does not provide information on LABETALOL's effect on mortality risk after myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"Passage 3 states that ATENOLOL decreases the risk of mortality after myocardial infarction, with evidence from the International Study of Infarct Survival [0m[32m([0m[32mISIS-1[0m[32m)[0m[32m suggesting a benefit in [0m
[32mreducing cardiovascular mortality."[0m[32m,[0m
[32m      [0m[32m"Given that two of the beta blockers [0m[32m([0m[32mMETOPROLOL TARTRATE and ATENOLOL[0m[32m)[0m[32m have strong evidence supporting a decrease in mortality risk after myocardial infarction, and one beta blocker [0m[32m([0m[32mLABETALOL[0m[32m)[0m
[32mhas no information available, it can be cautiously inferred that there is evidence suggesting that beta blockers as a category may decrease the risk of mortality after myocardial infarction. However, [0m
[32mwithout comprehensive data on all beta blockers, the effect for the category as a whole is not definitively established."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"There is evidence suggesting that beta blockers as a category may decrease the risk of mortality after myocardial infarction, but the effect for the category as a whole is not [0m
[32mdefinitively established due to lack of comprehensive data."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-mortality after myocardial infarction-beta blocker[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0moverall-effect-mortality after myocardial infarction-beta blocker[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0moverall-effect-mortality after myocardial infarction-beta blocker[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does the beta blocker category of drugs increase the risk of mortality after myocardial infarction, decrease it, or is there no clear effect?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"Passage 1 indicates that METOPROLOL TARTRATE decreases the risk of mortality after myocardial infarction, based on a large clinical study showing a 36% reduction in 3-month mortality."[0m[34m,[0m
[34m      [0m[34m"Passage 2 does not provide information on LABETALOL's effect on mortality risk after myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"Passage 3 states that ATENOLOL decreases the risk of mortality after myocardial infarction, with evidence from the International Study of Infarct Survival [0m[34m([0m[34mISIS-1[0m[34m)[0m[34m suggesting a benefit in [0m
[34mreducing cardiovascular mortality."[0m[34m,[0m
[34m      [0m[34m"Given that two of the beta blockers [0m[34m([0m[34mMETOPROLOL TARTRATE and ATENOLOL[0m[34m)[0m[34m have strong evidence supporting a decrease in mortality risk after myocardial infarction, and one beta blocker [0m[34m([0m[34mLABETALOL[0m[34m)[0m
[34mhas no information available, it can be cautiously inferred that there is evidence suggesting that beta blockers as a category may decrease the risk of mortality after myocardial infarction. However, [0m
[34mwithout comprehensive data on all beta blockers, the effect for the category as a whole is not definitively established."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"There is evidence suggesting that beta blockers as a category may decrease the risk of mortality after myocardial infarction, but the effect for the category as a whole is not [0m
[34mdefinitively established due to lack of comprehensive data."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does the beta blocker category of drugs increase the risk of mortality after myocardial infarction, decrease it, or is there no clear effect?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. Passage [0m[1;31m1[0m[31m indicates that METOPROLOL TARTRATE decreases the risk of mortality after myocardial infarction, based on a large clinical study showing a [0m[1;31m36[0m[31m% reduction in [0m[1;31m3[0m[31m-month mortality.[0m
[1;31m2[0m[31m. Passage [0m[1;31m2[0m[31m does not provide information on LABETALOL's effect on mortality risk after myocardial infarction.[0m
[1;31m3[0m[31m. Passage [0m[1;31m3[0m[31m states that ATENOLOL decreases the risk of mortality after myocardial infarction, with evidence from the International Study of Infarct Survival [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m suggesting a benefit in reducing [0m
[31mcardiovascular mortality.[0m
[1;31m4[0m[31m. Given that two of the beta blockers [0m[1;31m([0m[31mMETOPROLOL TARTRATE and ATENOLOL[0m[1;31m)[0m[31m have strong evidence supporting a decrease in mortality risk after myocardial infarction, and one beta blocker [0m[1;31m([0m[31mLABETALOL[0m[1;31m)[0m[31m has[0m
[31mno information available, it can be cautiously inferred that there is evidence suggesting that beta blockers as a category may decrease the risk of mortality after myocardial infarction. However, [0m
[31mwithout comprehensive data on all beta blockers, the effect for the category as a whole is not definitively established.[0m
[31m        -----[0m
[31m        Final answer: There is evidence suggesting that beta blockers as a category may decrease the risk of mortality after myocardial infarction, but the effect for the category as a whole is not [0m
[31mdefinitively established due to lack of comprehensive data.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0moverall-effect-mortality after myocardial infarction-beta blocker[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0moverall-effect-mortality after myocardial infarction-beta blocker[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was [0m
[31mprovided.[0m
 [1m([0moverall-effect-mortality after myocardial infarction-beta blocker[1m)[0m [31m Entity.USER [0m
 [1m([0moverall-effect-mortality after myocardial infarction-beta blocker[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0moverall-effect-mortality after myocardial infarction-beta blocker[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mcategory_effect_tool[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"category_effect_tool"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"label"[0m[32m: [0m[32m"decrease"[0m[32m,[0m
[32m    [0m[32m"confidence"[0m[32m: [0m[1;32m0.75[0m[32m,[0m
[32m    [0m[32m"probability"[0m[32m: [0m[1;32m0.9[0m[32m,[0m
[32m    [0m[32m"frequency"[0m[32m: [0m[32m"common"[0m[32m,[0m
[32m    [0m[32m"evidence"[0m[32m: [0m[32m"strong"[0m[32m,[0m
[32m    [0m[32m"justification"[0m[32m: [0m[32m"Evidence from large clinical studies, such as the one cited for METOPROLOL TARTRATE and the International Study of Infarct Survival [0m[32m([0m[32mISIS-1[0m[32m)[0m[32m for ATENOLOL, indicates a significant[0m
[32mdecrease in mortality after myocardial infarction. While comprehensive data for all beta blockers is not available, the strong evidence from these studies suggests that beta blockers as a category are[0m
[32mlikely to decrease the risk of mortality after myocardial infarction. The confidence is not absolute due to the lack of information on some beta blockers, such as LABETALOL, but the available evidence[0m
[32mfrom multiple studies supports a common and strong association with decreased mortality risk."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-mortality after myocardial infarction-beta blocker[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mcategory_effect_tool[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m
